Objective Antibodies against contactin-associated protein-like 2 (CASPR2-Abs) have been described in acquired neuromyotonia, limbic encephalitis (LE) and Morvan syndrome (MoS). However, it is unknown ...

Background and purpose To investigate early clinical surrogates for long-term independency of patients treated with thrombectomy for large vessel occlusion stroke in daily clinical routine. Methods ...

Objectives This longitudinal study compared emerging plasma biomarkers for neurodegenerative disease between controls, patients with Alzheimer’s disease (AD), Lewy body dementia (LBD), frontotemporal ...

3 Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy 4 Department of Neurology/Stroke Unit, San Maurizio Hospital, Bolzano, Italy 5 ...

Background Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a ...

Objective To compare acute treatment responses and long-term outcome in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis. Methods Retrospective case series of 118 patients with LGI1 ...

Objective The Tysabri Observational Programme (TOP), which began >10 years ago, is an open-label, multinational, prospective observational study evaluating the long-term safety and effectiveness of ...

Correspondence to Dr Robert Steinbach, Department of Neurology, Jena University Hospital, Jena 07747, Thüringen, Germany; Robert.Steinbach{at}med.uni-jena.de Amyotrophic lateral sclerosis (ALS) is a ...

Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and alien limb phenomenon.

MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK Correspondence to Professor Mary M Reilly, MRC Centre for ...

Objective It has been debated whether the different clinical disease courses in multiple sclerosis (MS) are the consequence of different pathogenic mechanisms, with distinct risk factors, or if all MS ...

FIREFISH (NCT02913482) in Type 1 SMA (inclusion criteria [IC]: aged 1–7 months at enrollment) SUNFISH (NCT02908685) in Types 2/3 SMA (IC: aged 2–25 years at enrollment) JEWELFISH (NCT03032172) in SMA ...